A survey of Scripps Health clinicians reveals that specialty and personal risk assessment of side effects drive the chronic cough treatment gap.

Biologic therapy during pregnancy was not associated with adverse outcomes for most patients in a retrospective study presented at AAAAI 2026.

Patients with hereditary angioedema report significant unmet needs, including high costs and insurance barriers, according to data from AAAAI 2026.

Mepolizumab reduces moderate to severe COPD exacerbations in patients with varying blood eosinophil counts and type 2 inflammation.

A retrospective cohort study of 210,000 pediatric patients showed ICS therapy did not elevate the risk for pediatric fractures.

New data reveal that episodic lack of disease control in chronic spontaneous urticaria is linked to increased hospitalizations and outpatient visits.

Lebrikizumab is an interleukin-13 antagonist approved as Ebglyss for the treatment of adults and pediatric patients with moderate to severe atopic dermatitis.

Asthma exacerbation risk appeared to be reduced in patients receiving treatment with certain immune checkpoint inhibitors (ICIs), according to study results presented at the American Academy of ...

The data suggest significant challenges in maintaining long-term disease control with advanced systemic therapies for atopic dermatitis.

A systematic review shows second generation antihistamines appear to be more effective and less sedating for patients managing chronic urticaria.

Montelukast is a leukotriene receptor antagonist approved for the prophylactic and chronic treatment of asthma and the relief of allergic rhinitis.

COVID vaccines are back under review and the move is raising concern among some health experts. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is slated ...